Keyword | CPC | PCC | Volume | Score | Length of keyword |
---|---|---|---|---|---|
nivolumab melanoma | 1.09 | 1 | 3816 | 12 | 18 |
nivolumab | 0.72 | 0.2 | 5249 | 60 | 9 |
melanoma | 1.13 | 0.3 | 7659 | 29 | 8 |
Keyword | CPC | PCC | Volume | Score |
---|---|---|---|---|
nivolumab melanoma | 0.78 | 0.2 | 7791 | 22 |
nivolumab melanoma approval | 1.3 | 0.7 | 6224 | 8 |
nivolumab melanoma eviq | 0.57 | 1 | 5587 | 1 |
nivolumab melanoma fda | 0.57 | 0.6 | 3690 | 89 |
nivolumab melanoma study | 0.64 | 0.3 | 2314 | 17 |
nivolumab melanoma adjuvant | 1.62 | 0.1 | 2198 | 33 |
nivolumab melanoma treatment | 0.24 | 0.4 | 8492 | 26 |
nivolumab melanoma effetti collaterali | 1.01 | 0.9 | 9287 | 27 |
pembrolizumab versus nivolumab for melanoma | 1.74 | 0.3 | 919 | 9 |
nivolumab and pembrolizumab for melanoma | 0.87 | 0.8 | 5317 | 64 |
relatlimab nivolumab melanoma | 1.17 | 0.2 | 8607 | 60 |
ipilimumab and nivolumab melanoma | 1.9 | 0.5 | 1490 | 7 |
pembrolizumab vs nivolumab melanoma | 1.73 | 0.2 | 1014 | 97 |
relatlimab nivolumab melanoma fda approval | 1.09 | 0.6 | 8762 | 1 |
fda approval nivolumab melanoma | 0.76 | 0.5 | 5131 | 83 |
nivolumab nice approval melanoma | 1.48 | 0.5 | 9586 | 9 |